NCT05216172View on ClinicalTrials.gov

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

PHASE2CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

September 11, 2022

Study Completion Date

September 11, 2022

Conditions

Type 2 DiabetesDiabetes Mellitus, Type 2Renal TransplantKidney Transplant; ComplicationsEnd Stage Renal Disease

Interventions

DRUG

AZD1656

active drug

DRUG

Placebo

placebo

Trial Locations (1)

E1 1BB

Royal London Hospital Barts Health NHS Trust, London

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Queen Mary University of London

OTHER